Money spent on community-based HIV prevention translates into treatment savings
Every $1 spent on community-based HIV prevention programs in Ontario saves $5 in treatment costs, a new study has found.
Jul 9, 2015
0
63
Every $1 spent on community-based HIV prevention programs in Ontario saves $5 in treatment costs, a new study has found.
Jul 9, 2015
0
63
(HealthDay)—Specific biomarkers correlate with cardiovascular dysfunction and all-cause mortality among HIV-infected individuals, according to a study published online July 8 in JACC: Heart Failure.
Jul 9, 2015
0
10
Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample ...
Jun 4, 2015
0
43
HIV has a voracious sweet tooth, which turns out to be its Achilles' heel, reports a new study from Northwestern Medicine and Vanderbilt University.
May 28, 2015
0
41
(HealthDay)—People with HIV should start taking medications to battle the virus that causes AIDS as soon as they're diagnosed, a new international study finds.
May 28, 2015
0
12
A team led by researchers from UC San Francisco, Organic Health Response, and Microclinic International is reporting results of a study that showed significant benefits of microclinics—an innovative intervention that mobilized ...
May 18, 2015
0
14
In patients with HIV, a diabetes drug may have benefits beyond lowering blood sugar. A new study from researchers at Washington University School of Medicine in St. Louis suggests the drug may prevent cardiovascular problems ...
May 14, 2015
0
88
In the first-of-its-kind study since the passage of the HIV Organ Policy Equity Act (the HOPE Act), which lifted the ban on organ donations from one HIV-positive person to another, Penn Medicine researchers report on the ...
May 14, 2015
0
25
Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks ...
Apr 23, 2015
0
11
A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response ...
Apr 23, 2015
0
2